Hinke A - Search Results

1

Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes.

Schanz J, Jung H, Wörmann B, Gassmann W, Petersen T, Hinke A, Haase D. Schanz J, et al. Among authors: hinke a. Leuk Res. 2009 Sep;33(9):1183-8. doi: 10.1016/j.leukres.2009.03.027. Epub 2009 May 2. Leuk Res. 2009. PMID: 19411105 Clinical Trial.

2

Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?

Vacha P, Fehlauer F, Mahlmann B, Marx M, Hinke A, Sommer K, Richter E, Feyerabend T. Vacha P, et al. Among authors: hinke a. Strahlenther Onkol. 2003 Jun;179(6):385-9. doi: 10.1007/s00066-003-1016-1. Strahlenther Onkol. 2003. PMID: 12789464 Clinical Trial.

3

Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population.

Ludwig H, Pönisch W, Knop S, Egle A, Hinke A, Schreder M, Lechner D, Hajek R, Gunsilius E, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Rumpold H, Pour L, Jelinek T, Krenosz KJ, Meckl A, Nolte S, Melchardt T, Greil R, Zojer N. Ludwig H, et al. Among authors: hinke a. Leuk Lymphoma. 2020 Feb;61(2):377-386. doi: 10.1080/10428194.2019.1666381. Epub 2019 Sep 26. Leuk Lymphoma. 2020. PMID: 31556753 Free article.

4

[Evaluation of the complementary drug Factor AF2 as a supportive agent in management of advanced urothelial carcinoma. Prospective randomized multicenter study].

Krege S, Hinke A, Otto T, Rübben H. Krege S, et al. Among authors: hinke a. Urologe A. 2002 Mar;41(2):164-8. doi: 10.1007/s001200100129. Urologe A. 2002. PMID: 11993095 Clinical Trial. German.

5

Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis.

Jordan K, Hinke A, Grothey A, Schmoll HJ. Jordan K, et al. Among authors: hinke a. Support Care Cancer. 2005 Jan;13(1):26-31. doi: 10.1007/s00520-004-0672-8. Epub 2004 Nov 18. Support Care Cancer. 2005. PMID: 15668744

6

Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.

Dunst J, Debus J, Rudat V, Wulf J, Budach W, Hoelscher T, Reese T, Mose S, Roedel C, Zuehlke H, Hinke A. Dunst J, et al. Among authors: hinke a. Strahlenther Onkol. 2008 Sep;184(9):450-6. doi: 10.1007/s00066-008-1751-4. Epub 2008 Sep 19. Strahlenther Onkol. 2008. PMID: 19016023 Clinical Trial.

7

[Supportive treatment with megestrol acetate during radio(chemo)therapy in patients with tumors in the head-neck area. A randomized study].

Fietkau R, Riepl M, Kettner H, Hinke A, Sauer R. Fietkau R, et al. Among authors: hinke a. Strahlenther Onkol. 1996 Mar;172(3):162-8. Strahlenther Onkol. 1996. PMID: 8721265 Clinical Trial. German.

8

Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer.

Rödel C, Arnold D, Hipp M, Liersch T, Dellas K, Iesalnieks I, Hermann RM, Lordick F, Hinke A, Hohenberger W, Sauer R. Rödel C, et al. Among authors: hinke a. Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1081-6. doi: 10.1016/j.ijrobp.2007.07.2356. Epub 2007 Sep 19. Int J Radiat Oncol Biol Phys. 2008. PMID: 17881150 Clinical Trial.

9

Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials.

Weiss C, Arnold D, Dellas K, Liersch T, Hipp M, Fietkau R, Sauer R, Hinke A, Rödel C. Weiss C, et al. Among authors: hinke a. Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):472-8. doi: 10.1016/j.ijrobp.2009.07.1718. Epub 2010 Feb 3. Int J Radiat Oncol Biol Phys. 2010. PMID: 20133081

10

Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer.

Hecht M, Eckstein M, Rutzner S, von der Grün J, Illmer T, Klautke G, Laban S, Hautmann MG, Brunner TB, Tamaskovics B, Hinke A, Zhou JG, Frey B, Donaubauer AJ, Becker I, Semrau S, Hartmann A, Balermpas P, Budach W, Gaipl US, Iro H, Gostian AO, Fietkau R. Hecht M, et al. Among authors: hinke a. J Immunother Cancer. 2022 Jan;10(1):e003747. doi: 10.1136/jitc-2021-003747. J Immunother Cancer. 2022. PMID: 35078923 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

125 results

Search Page

Filters